

Special Issue

State-of-the-Art Neurophysiology and Biochemistry of Brain Diseases in Europe

Message from the Guest Editors

We are pleased to announce a volume dedicated to the state of the art in the biochemistry and pathophysiology of the brain. The medical, social, and economic impact of age-related neurodegenerative diseases is immense, and is increasing rapidly as life expectancy is extended and the average age of the population shifts upward. These disorders, which include Alzheimer's disease, Parkinson's disease, prion diseases and amyotrophic lateral sclerosis, are due to the misfolding and aggregation of key brain proteins. Multiple sclerosis is another chronic neurological condition that is the subject of intensive research. All these disorders are related to perturbations in key cellular and molecular pathways, including those related to protein folding and degradation, neuronal plasticity, and inflammation. Recently, emerging and novel biomarkers have been identified and validated, and have had a huge impact on patients' outcomes and improved the treatment landscape. We cordially invite experts in the field to submit original research or review articles pertaining to this important and fast-progressing field of biomedicine.

Guest Editors

Prof. Dr. Rosanna Di Paola

Dr. Marika Cordaro

Dr. Roberta Fusco

Deadline for manuscript submissions

closed (31 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/112888

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).